- Company
- AbbVie Korea launches new glaucoma treatment 'XEN 63'
- by Whang, byung-woo Jul 3, 2025 06:08am
- AbbVie Korea announced on July 1 that it has launched XEN 63, a new option for glaucoma treatment in patients whose intraocular pressure (IOP) is not controlled by previous glaucoma surgery or existing medicines. With the expansion of the XEN Gel Implant portfolio, including XEN 45, patients now have a wider range of personalized treatment
- Company
- Leclaza combination therapy takes over Europe
- by Moon, sung-ho Jul 3, 2025 06:07am
- Leclaza (lazertinib), a new lung cancer drug developed by Yuhan Corporation, has been officially included in the European Society for Medical Oncology (ESMO) guidelines. Reflecting the latest clinical study findings, Leclaza in combination with Rybrevant (amivantamab, Johnson & Johnson) has been included as a first-line option in the guidelin
- Company
- ‘TNF-α inhibitors, a cornerstone for rheumatoid arthritis'
- by Whang, byung-woo Jul 2, 2025 06:09am
- Rheumatoid arthritis is a chronic autoimmune condition that causes inflammation in the joints, leading to pain and deformity. Its prevalence in Korea is estimated to be approximately 0.5&8211;1% Recently, with the development of new treatments and improved awareness of the disease, early diagnosis rates are on the rise. In fact, over the
- Company
- K-CAB·Entresto awaiting the Supreme Court rulings
- by Kim, Jin-Gu Jul 2, 2025 06:09am
- Patent disputes involving blockbuster drugs, K-CAB (tegoprazan) and Entresto (valsartan/sacubitril), are reaching their final stages. Observations suggest that the Supreme Court's final ruling could come as early as the second half of this year. K-CAB's annual prescription sales amount to KRW 200 billion, while Entresto's are KRW 70 billion.
- Company
- Generics of Jardiance expected to compete for KRW 100B mkt
- by Kim, Jin-Gu Jul 2, 2025 06:08am
- The substance patent for Jardiance (empagliflozin), a diabetes treatment generating annual sales of approximately KRW 100 billion, is set to expire this October. Generic competition in the SGLT-2 inhibitor diabetes drug market is likely to heat up again. Approximately 50 companies have already secured approvals for related generic products
- Company
- Asthma drug 'Trelegy 200 Ellipta Inhaler' becomes available
- by Eo, Yun-Ho Jul 1, 2025 06:03am
- The asthma treatment 'Trelegy 200 Ellipta Inhaler' is now available for prescription at tertiary general hospitals. According to industry sources, Trelegy 200 Ellipta Inhaler (fluticasone furoate·umeclidinium·vilanterol) has passed the drug committees (DC) of Korea's 'Big 5' tertiary general hospitals, including Samsung Medical Center,
- Company
- Dong-A ST-Ipsen to comarket prostate cancer drug Diphereline
- by Son, Hyung Min Jul 1, 2025 06:02am
- Dong-A ST (CEO Jae-Hoon Jeong) announced on the 30th that it has signed a joint sales agreement with Ipsen Korea (CEO Mi-sun Yang) for the premature puberty and prostate cancer treatment ‘Diphereline.’ Diphereline is a GnRH (gonadotropin-releasing hormone) agonist developed by the multinational biopharmaceutical company Ipsen, used to
- Company
- Metabolic disease drug development landscape evolves
- by Son, Hyung Min Jul 1, 2025 06:02am
- Innovative efforts in the development of new drugs for metabolic disorders such as obesity and diabetes are steadily gaining traction in Korea and abroad. The success of standalone GLP-1 therapies has driven the evolution toward multi-hormonal agents, and recently, major global pharmaceutical companies and biotech firms are accelerating new drug
- Company
- AstraZeneca Korea launches ‘Lung Health Checkbus’ campaign
- by Whang, byung-woo Jul 1, 2025 06:00am
- AstraZeneca Korea announced on the 30th that it held a ceremony for the launch of its ‘Lung Health Checkbus’ campaign at the COEX Square in Seoul on the 27th. The campaign aims to help people detect lung nodules that they are not aware of at an early stage by operating buses equipped with AI-based chest X-ray imaging nationwide. Ast
- Company
- New K-drugs for metabolic diseases make international debut
- by Son, Hyung Min Jun 30, 2025 06:07am
- Major Korean pharmaceutical and biotechnology companies have signaled their full-scale entry into global clinical trials, presenting new drug development results at overseas conferences. The companies presented their achievements in developing new drugs for various metabolic diseases, including obesity, type 2 diabetes, and metabolic dysfunction
